| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In a dose- and time-dependent manner, desmethylglycitein (4',6,7-TriHydroxyisoflavone) (0-100 μM; 24-72 hours) inhibits the anchorage-dependent growth of HCT-116 and DLD1 cells without causing cytotoxicity[1]. In a dose-dependent manner, desmethylglycitein (4',6,7-TriHydroxyisoflavone) (0-100 μM; 24-72 hours) inhibits both CDK1 and CDK2 activity in HCT-116 cells [1]. Cell cycle arrest is induced in S and G2/M phases by desmethylglycitein (4',6,7-TriHydroxyisoflavone) (0-100 μM; 24-72 hours), with a higher percentage of cells in S phase at 100 μM6,7. In the 4'-THIF treatment group, the same pattern was observed in the G2/M phase (29.5% vs. 19.1%) [1].
|
|---|---|
| ln Vivo |
In addition to acting as a potent anticancer treatment, desmethylglycitein (4',6,7-trihydroxyisoflavone) (ip; 5 or 25 mg/kg; once daily; 20 days) inhibits the growth of tumors in mice and may also prevent or postpone the tumorigenicity of HCT-116 cells in an in vivo system [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HCT-116 Cell Tested Concentrations: 0, 12.5, 25, 50 or 100 μM Incubation Duration: 24, 48 or 72 hrs (hours) Experimental Results: Inhibition of anchorage-dependent and -independent inhibition of HCT-116 cells grow. Western Blot Analysis [1] Cell Types: HCT-116 and DLD1 cells Tested Concentrations: 0, 25, 50 or 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibition of CDK1 and CDK2 expression. Cell cycle analysis[1] Cell Types: HCT-116 Cell Tested Concentrations: 0, 25, 50 or 100 μM Incubation Duration: 24, 48 or 72 hrs (hours) Experimental Results: Induced cell cycle of HCT-116 cells in S phase and G2/M phase Stagnation. |
| Animal Protocol |
Animal/Disease Models: Female athymic nude mice were injected subcutaneously (sc) (sc) with HCT-116 cells [1]
Doses: 5 or 25 mg/kg Route of Administration: intraperitoneal (ip) injection; 5 or 25 mg/kg; one time/day; 20-day Experimental Results: HCT-116 xenogeneic Tumor growth, size, and weight of the grafts were diminished. |
| References |
|
| Additional Infomation |
4',6,7-trihydroxyisoflavone is a hydroxyisoflavone that is daidzein bearing an additional hydroxy substituent at position 6. It has a role as a metabolite, a PPARalpha agonist, a PPARgamma agonist, an anti-inflammatory agent, an antimutagen and an EC 1.14.18.1 (tyrosinase) inhibitor. It is functionally related to a daidzein.
6,7,4'-Trihydroxyisoflavone has been reported in Capsicum annuum with data available. |
| Molecular Formula |
C15H10O5
|
|---|---|
| Molecular Weight |
270.2369
|
| Exact Mass |
270.053
|
| CAS # |
17817-31-1
|
| PubChem CID |
5284649
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.548g/cm3
|
| Boiling Point |
587.1ºC at 760mmHg
|
| Melting Point |
322 °C
|
| Flash Point |
229.7ºC
|
| Vapour Pressure |
2.21E-14mmHg at 25°C
|
| Index of Refraction |
1.732
|
| LogP |
2.576
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
411
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
GYLUFQJZYAJQDI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-14-6-13(18)12(17)5-10(14)15(11)19/h1-7,16-18H
|
| Chemical Name |
6,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~462.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.70 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7004 mL | 18.5021 mL | 37.0041 mL | |
| 5 mM | 0.7401 mL | 3.7004 mL | 7.4008 mL | |
| 10 mM | 0.3700 mL | 1.8502 mL | 3.7004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
